SITC Press Releases

SITC Announces EU Immuno-oncology Drug Development Summit - Bringing the European IO Community Together to Foster the Next Wave of IO Therapeutics

By Thomas Martin posted 3 days ago
Keynote Address featuring Dr. E. John Wherry – “Intersection of IO and Autoimmunity” MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce the upcoming EU Immuno-oncology Drug Development Summit, taking place in Lausanne, Switzerland on Sept. 3–4, 2026, at the Agora Cancer Research Center. As the world’s leading member-driven society dedicated to professionals working in cancer immunotherapy, SITC is uniquely positioned to bring together the entire immuno-oncology ecosystem. The EU Immuno-oncology Drug Development Summit will facilitate understanding, ...
0 comments

SITC and CRI Launch Annual Collaboration Bringing the Prestigious CRI William B. Coley Award Lecture to the SITC Annual Meeting

By Thomas Martin posted 4 days ago
NK cell pioneer Éric Vivier, DVM, PhD, to deliver the inaugural lecture at SITC 2026 MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) and t he Cancer Research Institute (CRI) are proud to announce the CRI William B. Coley Award Lecture will be presented at the 41 st Annual Meeting and Pre-Conference Programs (SITC 2026), reflecting the shared commitment of both organizations to celebrating scientific excellence at the world's leading forum dedicated exclusively to cancer immunotherapy. Éric Vivier, DVM, PhD, holder of the Natural Killer (NK) Cell Chair ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 12 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor Hematopoietic Stem Cell Transplantation for Adults with Hematologic Malignancies

By SITC Communications posted 24 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of Triple-Negative Breast Cancer

By SITC Communications posted 25 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of renal cell carcinoma

By SITC Communications posted 26 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC 2026 Keynote and Registration Press Release

By Thomas Martin posted 05-20-2026
SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41 st Annual Meeting The largest cancer immunotherapy conference featuring the latest research in immuno-oncology MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Ton Schumacher, PhD from the Netherlands Cancer Institute as the Keynote Speaker at its 41 st Annual Meeting and Pre-Conference Programs (SITC 2026) with his presentation “T Cell Recognition of Human Cancer: 'Cracking the Code' ”. SITC also hosts Catherine J. Wu, MD from the Dana-Farber Cancer ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

By SITC Communications posted 03-23-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 03-06-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 12-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 11-24-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications

By SITC Communications posted 11-20-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

By SITC Communications posted 10-13-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive-Stage Small Cell Lung Cancer

By SITC Communications posted 10-03-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection

By SITC Communications posted 09-22-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments